Table 6 Recurrence—ground glass tumors

Ordered by degree of confidence that results reflect the effect of the treatment, resection type, stage

First author year (reference)	Study characteristics					Confid RE Tmt effect	Duration of f/u (mo)	Unmatched overall recurrence %		Unmatched locoregional recurrence %		Adjusted RFS/DFS W/Seg vs. Lobe		Adjusted FFR W/Seg vs. Lobe		Comments
	Source	Yrs	n	Lobe vs.:	Stage [a]			W/Seg	Lobe	W/Seg	Lobe	HR	P	HR	P	
GGN																
Tsutani 2014 (132)	Japan ×4	05-10	239	SL	cIA [b]	M	42	1	1	0	0	1.27	NS			Adeno, CTR <0.5
Tsutani 2013 (121)	Japan ×4	05-10	162 [c]	Seg	cIA	M	43	-	-	3	4	-	NS			Adeno, Many GGN
Okada 2006 (122)	Japan ×3	92-01	567	Seg [d]	cIA1,2	L	72/71	**14**	17	5	7	1.24	NS	-	-	Healthy patients with GGN
Nishio 2016 (136)	Japan ×1	95-09	190	Seg	cIA1,2	VL	84/107	-	-	20	**6**	[1.65] [e]	NS	[3.54] [e]	.02	CTR >0.5
Kodama 2016 (124)	Japan ×1	97-10	138 [c]	Seg [f]	cIA1,2	VL	77/82	**4**	17	**4**	7	[1.99] [e]	NS			Excluding pure GGN
Chiang 2020 (125)	China ×1	11-16	568 [d]	SL	cIA	VL	38	**5**	18	1	2	0.67	NS	-	-	CTR <0.5 in 56%
Okada 2014 (126)	Japan ×1	05-?	200 [c]	Seg	cIA	VL	-	-	-	2	4	0.72	NS	-	-	Adeno

Inclusion criteria: studies reporting RFS, DFS or FFR using multivariate or propensity adjustment to compare wedge resection or segmentectomy vs. lobectomy, 2000–21, >50 pts per arm, ground-glass or screen-detected tumors. The HR reference is lobectomy, i.e., HR >1 reflects worse outcome compared with lobectomy. Bold highlights better outcome (>2-point difference); Red font highlights potential weakness, e.g., accrual occurring primarily before 2000; Light green shading highlights statistically significant difference.

[a], 8th edition (reported stage is translated into current 8th edition nomenclature for the sake of uniformity and contemporary application); [b], used solid tumor size (average for study 2 mm); [c], matched pairs (total); [d], predominantly (≥80%); [e], locoregional recurrence (shown in brackets because it is not comparable to any recurrence); [f], ~50% were "lobe-like" segments (left upper tri-segmentectomy, lingulectomy or basilar quadri-segmentectomy).

Adeno, adenocarcinoma; Conf RE tmt effect, confidence that results reflect the effect of the treatment (lobectomy or SL resection) vs. confounding factors; DFS, disease free survival; FFR, freedom from recurrence (only recurrence counts as an event); f/u, follow up duration (months); GGN, ground glass nodule; HR, hazard ratio; L, low confidence; Lobe, lobectomy; M, moderate confidence; NS, not statistically significant; RFS, recurrence free survival; Seg, segmentectomy; SL, sublobar resection (segmentectomy or wedge); W, wedge; VL, very low confidence; Yrs, years (of patient accrual).